Premium
A New clinical score for disease activity in Langerhans cell histiocytosis
Author(s) -
Donadieu Jean,
Piguet C.,
Bernard F.,
Barkaoui M.,
Ouache M.,
Bertrand Y.,
Ibrahim H.,
Emile J.F.,
Hermine O.,
Tazi A.,
Genereau T.,
Thomas C.
Publication year - 2004
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.20160
Subject(s) - medicine , langerhans cell histiocytosis , disease , histiocytosis , scoring system
Objective To develop an objective tool for assessing disease activity in patients with Langerhans cell histiocytosis (LCH). Method Scoring system was developed and applied to a database containing information on 612 patients. Results At diagnosis, the score distribution was highly asymmetrical: the score was between 0 and 2 in 74% of cases, 3–6 in 16%, 7–10 in 3%, and more than 10 in 6%. The 5‐year mortality rates were 1, 4.4, and 43.4%, respectively, among patients with initial scores of 0–2, 3‐6, and >6. Stability or an increase of the score at 6 weeks was highly predictive of death among patients with initial scores above 6, while score stability had no significant impact on vital outcome among patients with low or moderate scores at diagnosis. Conclusions This LCH disease activity score provides an objective tool for assessing disease severity, both at diagnosis and during follow‐up and treatment. © 2004 Wiley‐Liss, Inc.